Jefferies Financial Group Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 147.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,476 shares of the medical research company's stock after acquiring an additional 30,108 shares during the period. Jefferies Financial Group Inc.'s holdings in IQVIA were worth $9,919,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new stake in IQVIA in the fourth quarter worth approximately $33,000. GKV Capital Management Co. Inc. bought a new stake in IQVIA in the fourth quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the 4th quarter worth $44,000. Zions Bancorporation N.A. grew its stake in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the 4th quarter valued at $60,000. 89.62% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on IQV shares. Barclays lowered their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. UBS Group lowered their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Mizuho lowered their target price on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $230.76.
Read Our Latest Stock Report on IQV
IQVIA Price Performance
Shares of IQVIA stock traded up $2.23 during trading on Friday, hitting $142.66. 2,227,287 shares of the company's stock traded hands, compared to its average volume of 1,514,419. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm's fifty day moving average price is $159.83 and its 200 day moving average price is $185.86. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a market cap of $24.68 billion, a PE ratio of 19.02, a PEG ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period in the previous year, the business earned $2.54 EPS. The firm's revenue was up 2.5% on a year-over-year basis. Analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
